Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

210
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
210
Measurement: Standard Units03:38

Measurement: Standard Units

82.3K
Every measurement provides three kinds of information: the size or magnitude of the measurement (a number), a standard of comparison for the measurement (a unit), and an indication of the uncertainty of the measurement. While the number and unit are explicitly represented when a quantity is written, the uncertainty is an aspect of the errors in the measurement results.
82.3K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

6.3K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.3K
Standard Enthalpy of Formation02:37

Standard Enthalpy of Formation

49.6K
Enthalpy changes are typically tabulated for reactions in which both the reactants and products are at the same conditions. A standard state is a commonly accepted set of conditions used as a reference point for the determination of properties under other different conditions. For chemists, the IUPAC standard state refers to materials under a pressure of 1 bar and solutions at 1 M and does not specify a temperature. Many thermochemical tables list values with a standard state of 1 atm. Because...
49.6K
Standard Electrode Potentials03:02

Standard Electrode Potentials

50.5K
On comparing the reactivity of silver and lead, it is observed that the two ionic species, Ag+ (aq) and Pb2+ (aq), show a difference in their redox reactivity towards copper: the silver ion undergoes spontaneous reduction, while the lead ion does not. This relative redox activity can be easily quantified in electrochemical cells by a property called cell potential. This property is commonly known as cell voltage in electrochemistry, and it is a measure of the energy which accompanies the charge...
50.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toxic lipid-induced epigenetic activation of ICAM1 in liver sinusoidal endothelium regulates myeloid-driven fibro-inflammatory response in MASH.

Hepatology (Baltimore, Md.)·2026
Same author

The interplay of sleep characteristics with health factors and gut microbiome.

Nature communications·2026
Same author

Longitudinal gut microbiota tracking reveals the dynamics of horizontal gene transfer.

Nature communications·2025
Same author

Distinct microbial and metabolic shifts characterize acute coronary syndrome and recovery.

iMeta·2025
Same author

DNA methylation of genes involved in lipid metabolism drives adiponectin levels and metabolic disease.

Diabetologia·2025
Same author

Advanced Dialogues: From Genomes to Microbiomes-A Cross-Disciplinary Journey.

Advanced genetics (Hoboken, N.J.)·2025

Related Experiment Video

Updated: Feb 14, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

17.0K

Assessing Nutraceuticals for Hepatic Steatosis: A Standardized In Vitro Approach.

Victoria E J M Palasantzas1,2, Dicky Struik1, Trijnie Bos1

  • 1Department of Pediatrics, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.

Nutrients
|February 13, 2026
PubMed
Summary
This summary is machine-generated.

Most nutraceuticals, including short-chain fatty acids (SCFAs) and antioxidants (AOXs), did not reduce liver fat in a standardized in vitro model. Vitamin E was an exception, while some compounds unexpectedly increased triglycerides, emphasizing the need for rigorous testing for metabolic-associated steatotic liver disease (MASLD) treatments.

Keywords:
Fa2N-4HepG2MASLDantioxidantsintracellular triglyceridesnutraceuticalspolyphenolsresmetiromshort-chain fatty acidssteatosis

More Related Videos

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
07:12

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

8.6K
Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
07:05

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet

Published on: January 3, 2017

9.4K

Related Experiment Videos

Last Updated: Feb 14, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

17.0K
Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
07:12

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

8.6K
Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
07:05

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet

Published on: January 3, 2017

9.4K

Area of Science:

  • Hepatology
  • Nutraceuticals
  • In vitro modeling

Background:

  • Metabolic-associated steatotic liver disease (MASLD) is a growing concern, with nutraceuticals like short-chain fatty acids (SCFAs) and antioxidants (AOXs) explored as potential treatments.
  • Existing in vitro studies on nutraceuticals for MASLD suffer from inconsistent methodologies, hindering reliable assessment of their efficacy.

Purpose of the Study:

  • To systematically evaluate the anti-steatotic potential of eight common nutraceuticals (three SCFAs and five AOXs) using a standardized in vitro assay.
  • To compare the efficacy of nutraceuticals against established anti-steatotic drugs in a validated cellular model of steatosis.

Main Methods:

  • A systematic literature review identified common experimental conditions for in vitro MASLD studies.
  • Developed and validated a standardized assay using HepG2 and Fa2N-4 cell lines, inducing steatosis with free fatty acids and fructose.
  • Quantified intracellular triglyceride levels to assess the preventive and therapeutic effects of nutraceuticals and positive control drugs.

Main Results:

  • Most tested SCFAs and AOXs failed to reduce intracellular triglycerides; vitamin E showed a modest effect.
  • Butyrate, berberine, and curcumin unexpectedly increased triglyceride accumulation in liver cells.
  • Resmetirom was the only effective anti-steatotic drug; Fa2N-4 cells demonstrated higher sensitivity than HepG2 cells.

Conclusions:

  • A standardized in vitro assay was established for evaluating anti-steatotic nutraceuticals.
  • SCFAs and AOXs generally lack consistent efficacy in reducing liver steatosis in vitro.
  • Rigorous, quantitative validation is crucial for assessing potential MASLD interventions.